Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Autor: Fallowfield, Lesley, Jenkins, Valerie, Kilkerr, Justine, Langridge, Carolyn, Monson, Kathryn, Jakobsen, Erik Hugger, Nielsen, Mette Holck, Linnet, Soeren, Knoop, Ann, Pivot, Xavier, Bonnefoi, Herve, Mousseau, Mireille, Zelek, Laurent, Bourgeois, Hugues, Lefeuvre, Claudia Plesse, Bachelot, Thomas, Petit, Thierry, Brain, Etienne, Levy, Christelle, Gligorov, Joseph, Augustin, Doris, Graf, Heiko, Heinrich, Georg, Kroening, Hendrik, Kuemmel, Sherko, Müller, Volkmar, Overkamp, Friedrich, Park-Simon, Tjoung-Won, Schmidt, Marcus, Perlova-Griff, Lidia, Wolf, Christopher, Colleoni, Marco, Ballestrero, Alberto, Bernardo, Antonio, Ribecco, Angela Stefania, Gianni, Luca, Curigliano, Giuseppe, Brewczynska, Elżbieta, Jassem, Jacek, Shirinkin, Vadim, Manikhas, Alexey, Dvornichenko, Victoria, Lichinitser, Mikhail, Semiglazov, Vladimir, Mukhametshina, Guzel, Bulavina, Irina, Arranz, Enrique Espinosa, Ocon, Francisco Carabantes, Vivanco, Guillermo López, Bofill, Javier Salvador, Quintela, Ignacio Porras, Muñoz, Alfonso Sanchez, Pérez, Yolanda Fernández, Espinosa, Javier Cassinello, Alvarez, José Valero, del Prado, Rodrigo Lastra, De Merino, LuisLa Cruz, García, José Manuel Pérez, Frances, Santos Enrech, Edlund, Per, Norberg, Bengt, Wennstig, Anna-Karin, Lind, Pehr, Hauser, Nik, Tausch, Christoph, Camci, Celalettin, Arpaci, Fikret, Abali, Huseyin, Uslu, Ruchan, Tahir, Saad, Wheatley, Duncan, Chan, Stephen, Barrett-Lee, Peter, McAdam, Karen, Simcock, Richard, Burcombe, Russell, El-Maraghi, Robert, Califaretti, Nadia, Spadafora, Silvana, Sehdev, Sandeep, Sami, Amer, Verma, Sunil, Pivot, X. ^*, Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L.

Publikováno v: In Annals of Oncology October 2014 25(10):1979-1987

Ribociclib-Related Stevens–Johnson Syndrome: Oncologic Awareness, Case Report, and Literature Review

Autor: Santos Enrech, Enrique Revilla, Héctor Muñoz-González, Pablo Tolosa, Ramón Yarza, Olga González-Valle, Victoria López-Gómez, Eva Ciruelos

Publikováno v: Journal of Breast Cancer

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis belong to a severe dermatopathic spectrum that includes frequently fatal mucocutaneous manifestations consisting of whole epidermal necrosis and sloughing with bullous transformation, blis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53ca5d9113428dc7845c33374bdebec1
http://europepmc.org/articles/PMC6933037

Ethanol-induced symptoms in patients receiving gemcitabine diluted from a concentrate for solution for infusion containing ethanol

Autor: José Miguel Martín Martínez, Teresa Molina-Garcia, Laura López-Esteban, Rocío Vázquez-Sánchez, Miguel Soria-Tristán, Laura Díaz-Paniagua, Ana Sanchez-Pena, Raúl Diez-Fernández, Santos Enrech-Frances

Publikováno v: Journal of Oncology Pharmacy Practice. 24:511-516

Purpose Ethanol as an excipient is used to enhance the solubility of gemcitabine, but, sometimes, the dose of ethanol a patient may be given is much higher than the dose considered to be toxic. We aimed to assess ethanol-related symptoms and signs in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24d6d40815898ae2db26751fb9f00738
https://doi.org/10.1177/1078155217715790

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Autor: Thomas Bachelot, Alberto Ballestrero, Marco Colleoni, José Valero Alvarez, Amer Sami, Celalettin Camci, Rodrigo Lastra del Prado, Luis De La Cruz Merino, Antonio Bernardo, Peter Barrett-Lee, Yolanda Fernández Pérez, Vladimir Semiglazov, Thierry Petit, Mette Holck Nielsen, C. Langridge, Guillermo López Vivanco, Nik Hauser, Ignacio Porras Quintela, José Manuel Pérez García, Anna-Karin Wennstig, Victoria Dvornichenko, Erik Jakobsen, Guzel Mukhametshina, Heiko Graf, V. Jenkins, Mireille Mousseau, Alfonso Sanchez Muñoz, Pehr Lind, Irina Bulavina, Alexey Manikhas, Bengt Norberg, Xavier Pivot, Per Edlund, Sandeep Sehdev, Valerie Jenkins, Santos Enrech Frances, Nadia Califaretti, V. Müller, G. Curigliano, Duncan Wheatley, Stephen L. Chan, Enrique Espinosa Arranz, S. Osborne, Soeren Linnet, Nana Scotto, J. Gligorov, Volkmar Müller, Tjoung-Won Park-Simon, Karen McAdam, Ann Knoop, Giuseppe Curigliano, X. Pivot, Justine Kilkerr, Georg Heinrich, L. Fallowfield, Francisco Carabantes Ocon, Christopher Wolf, Robert El-Maraghi, Hugues Bourgeois, Christelle Levy, Luca Gianni, Russell Burcombe, Vadim Shirinkin, Huseyin Abali, Etienne Brain, Christoph Tausch, Lidia Perlova-Griff, Claudia Plesse Lefeuvre, Joseph Gligorov, Mikhail Lichinitser, Friedrich Overkamp, S. Verma, Kathryn Monson, Angela Stefania Ribecco, Doris Augustin, Lesley Fallowfield, Saad Tahir, Javier Cassinello Espinosa, Marcus Schmidt, Jacek Jassem, Laurent Zelek, Ruchan Uslu, Richard Simcock, Sherko Kuemmel, Javier Salvador Bofill, A. Knoop, Hervé Bonnefoi, Fikret Arpaci, Silvana Spadafora, Sunil Verma, Hendrik Kroening, Elżbieta Brewczynska

Publikováno v: Annals of Oncology. 25:1979-1987

Patients with HER2-positive early breast cancer (EBC) preferred subcutaneous (s.c.) trastuzumab, delivered via single-use injection device (SID), over the intravenous (i.v.) formulation (Cohort 1 of the PrefHer study: NCT01401166). Here, we report pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b145cdce1456ae985a553171af8850a2
https://doi.org/10.1093/annonc/mdu364